Phase IV

Vopec Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Vopec Pharma completes COVID-19 clinical trials of herbal formulation, Amrta Karuna

Lead Product(s): Amrta Karuna

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2020

Details:

Notable results for the Amrta Karuna treatment group compared to the control showed Significant reduction in hospital quarantine (28% decrease) , Significantly reduced CRP inflammatory levels, RT-PCR negative on day 7 at 71.42% vs 42.85% , TLC within normal range.

Octapharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

South Africa

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients

Lead Product(s): Human Immune Globulin

Therapeutic Area: Infections and Infectious Diseases Product Name: Octagam

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group.

Glenmark

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Glenmark Commences 1000 Patients Post Marketing Surveillance Study With COVID-19 Who Are Administered FabiFlu®

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: FabiFlu

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 13, 2020

Details:

Glenmark has successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu® through its own in-house R&D team within the country, ensuring self-reliance with regard to longterm production and manufacturing.

Pankajakasthuri Herbal Research Foundation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Pankajakasthuri Announces Promising Interim Results for ZingiVir–H Among COVID-19 Patients

Lead Product(s): Zingivir-H

Therapeutic Area: Infections and Infectious Diseases Product Name: Zingivir-H

Highest Development Status: Phase IV Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 10, 2020

Details:

Clinical trials of ZingiVir-H, Pankajakasthuri’s new drug, are underway among 112 patients as an adjunct therapy for the pandemic as well as among 135 additional patients as a stand-alone treatment in a double-blind study.

Eisai

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Eisai to Investigate Eritoran in REMAP-COVID Study

Lead Product(s): Eritoran

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: The Global Coalition for Adaptive Research

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 01, 2020

Details:

The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites across the trial network, including Japan, will follow.

Dimerix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Global Remap-Cap Platform Trial Protocol to Include Dmx-200 in Covid-19 Patients

Lead Product(s): DMX-200

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IV Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

DMX-200 has been selected for inclusion in the protocol as a new treatment arm in the global the REMAP-CAP program aimed at treating patients with Acute Respiratory Distress Syndrome (ARDS) as a result of COVID-19.

Octapharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

South Africa

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Octapharma USA Extends Funding for COVID-19 Study Following Positive Preliminary Research Data

Lead Product(s): Human Immune Globulin

Therapeutic Area: Infections and Infectious Diseases Product Name: Octagam

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: University of California San Diego School of Medicine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding June 03, 2020

Details:

The randomized open label study is evaluating the standard of care (SOC) plus intravenous immunoglobulin (IVIG) compared to SOC alone in the treatment of COVID-19 infection, specifically in preventing mechanical ventilation in COVID-19 patients requiring high-flow oxygen.

Kings College London

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kings College London Launches Trial Investigating the Effectiveness of Ibuprofen in COVID-19 Patients

Lead Product(s): Ibuprofen

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

Trial to evaluate formulation of ibuprofen treatment for treating severe acute respiratory distress syndrome (ARDS), a complication of COVID-19, has launched in south London.

Defence Materials Technology Centre

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Certara and DMTC Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Workers at High Risk of COVID-19

Lead Product(s): Chloroquine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Certara

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2020

Details:

Certara will support the DMTC led clinical trial by analyzing study data to develop mathematical models to understand viral time course and factors impacting drug exposure and prophylactic response.

Royal Melbourne Hospital

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Australian Researchers Launch ASCOT Study for Covid-19

Lead Product(s): Hydroxychloroquine Sulphate

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2020

Details:

The AustralaSian COVID-19 Trial is attempting to see if already established treatments might prove effective against COVID-19 which as a ‘new disease’ has no current treatments.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Vopec Pharmaceuticals

Vopec Pharma completes COVID-19 clinical trials of herbal formulation, Amrta Karuna

Octapharma

Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients

Glenmark

Glenmark Commences 1000 Patients Post Marketing Surveillance Study With COVID-19 Who Are Administered FabiFlu®

Pankajakasthuri Herbal Research Foundation

Pankajakasthuri Announces Promising Interim Results for ZingiVir–H Among COVID-19 Patients

Eisai

Eisai to Investigate Eritoran in REMAP-COVID Study

Dimerix

Global Remap-Cap Platform Trial Protocol to Include Dmx-200 in Covid-19 Patients

Octapharma

Octapharma USA Extends Funding for COVID-19 Study Following Positive Preliminary Research Data

Kings College London

Kings College London Launches Trial Investigating the Effectiveness of Ibuprofen in COVID-19 Patients

Defence Materials Technology Centre

Certara and DMTC Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Workers at High Risk of COVID-19

Royal Melbourne Hospital

Australian Researchers Launch ASCOT Study for Covid-19